74: Targeting MUC1 as a Marker for Myeloid Leukemia Stem Cells by DC/AML Fusions  by Rosenblatt, J. et al.
30 Oral PresentationsHuman CD341 cells were isolated from umbilical cord blood,
stained with the membrane fluorescence marker PKH26, cultivated
in cytokine richmedia for five days and then sorted for their PKH26
fluorescence (dim versus bright, i.e. FDF versus SDF). Sorted cells
were injected into the tail vein of sublethally irradiatedNOD/SCID
mice (2  105 cells/animal). The animals were sacrificed at defined
time points from week 2 to 18 after transplantation. Flow cytomet-
ric analysis of the samples collected from the marrow, spleen, thy-
mus, and lymph nodes of the NOD/SCID mice indicated that
both SDF and FDFwere able to engraft the bone marrow of the an-
imals, i.e. erythroid and myeloid progenitor cells were recovered
from the bone marrow of SDF and FDF repopulated mice. The
most remarkable finding was that only cells of SDF origin were
found in the lymph nodes and thymus where, at week 15 they differ-
entiated into T cells. CD41CD81 double positive T progenitor
cells were recovered in the thymus and CD41 as well as CD81
T cells were present in the spleen and the lymph nodes. Until 18
weeks after reconstitution, very few B cells were present in the
spleen, whereas monocytes reached normal range. Global gene ex-
pression profiles of the two subpopulations (SDF and FDF) were
analyzed using a human transcriptome cDNA microarray. Several
molecular markers for stem cells were highly expressed in the
SDF as compared to FDF: CD133 (Prominin), MDR1 (multiple
drug resistance gene 1), clqr1 (complement component 1 receptor
1), Hoxa9, Cdx1 andHesx1 (which encode homeodomain proteins).
Our data indicated that SDF was enriched for primitive human
HSC, which were able to engraft in the thymus and lymph nodes
in the SCIDmouse model. These cells were able to give rise to pre-
cursor as well as mature T cells. Our results have provided unequiv-
ocal evidence that SDF is associated with primitive HSC function,
and is consistent with the results of differential gene expression
analysis in SDF. The significance of the cell-cell contacts in the
SCID model in maintaining stemness is currently being examined.
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TARGETING MUC1 AS A MARKER FOR MYELOID LEUKEMIA STEM CELLS
BY DC/AML FUSIONS
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The epithelial mucin antigen (MUC1) is aberrantly expressed in
many epithelial tumors and hematologic malignancies and has
served as a target for cellular immunotherapy. In this study, we ex-
aminedMUC1 as amarker formyeloid leukemia cells and their pro-
genitors. Myeloid leukemia cells were isolated from bone marrow
aspirates or peripheral blood. MUC1 was not expressed on unse-
lected leukemia cells (mean expression 3%, n 5 12). A subset of
samples underwent CD34 selection by magnetic bead separation.
In contrast to unselected cells, 38% of CD341 leukemia cells ex-
pressed MUC1 (n 5 5). The leukemia stem cell compartment was
isolated by separating CD341/CD38-/lineage- fractions by flow
cytometric sorting. Leukemia stem cells expressed MUC1 both by
immunohistochemistry and FACS analysis. Similarly, we examined
MUC1 expression on progenitor cells derived from chronic phase
CML and following blast transformation. MUC1 was seen in only
4% of CD341 cells obtained from chronic phase CML samples
(n 5 4) while uniform expression was observed in samples derived
from patients with accelerated/blast phase. These data suggest
that MUC1 serves as a marker for early leukemia progenitors and
is associated with blastic transformation. We assessed the capacity
of a dendritic cell (DC)/myeloid leukemia fusion cell vaccine to
stimulate immune responses that target MUC1 and other antigens
expressed by the stem cell compartment. DCs were generated from
adherent mononuclear cells cultured with GM-CS, IL-4 and
TNFa. DCs were fused with patient derived myeloid leukemia cells
using polyethylene glycol. Fusion cells were quantified by deter-
mining the percentage of cells that expressed unique DC and leuke-
mia antigens. Stimulation of autologous T cells with DC/AML
fusions resulted in a mean 3 fold increase in CD81 cells binding
the MUC1 tetramer (N5 4). DC/AML fusions stimulated anti-tu-
mor immune responses that targeted leukemia stem cells. Fusion
stimulated T cells demonstrated increased expression of IFNg fol-
lowing exposure to lysate generated from unselected leukemia cells(29 fold) and leukemia stem cells (28 fold). In contrast, exposure to
renal carcinoma lysate generated only a 5 fold increase in IFNg. In
summary, this data suggests that leukemic progenitors in AML and
accelerated/blast phase CML express MUC1. DC/tumor fusion
vaccines target MUC1 and the stem cell compartment, and may
be a potent immunotherapeutic strategy to eliminate the malignant
stem cell clone in AML.SUPPORTIVE CARE75
PREVENTION OF LATE CMV DISEASE AFTER HCT: A RANDOMIZED DOU-
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Background:LateCMVdisease is an important complication af-
ter allogeneicHCT. PCR surveillance followed by preemptive ther-
apy (PET) is costly and often not feasible. VGCV prophylaxis may
prevent late CMV-related complications. Methods: Between day
80 and day 120 after HCT, CMV seropositive or D1/R- allograft
recipients with CMV infection prior to day 80 or GVHDwere ran-
domized to receive VGCV prophylaxis (900 mg/day) or placebo
(Plac) until day 270. Patients were monitored weekly for CMV
DNA by plasma PCR, blood chemistry and CBC/differential. IV
GCV (5 mg/kg twice daily) or VGCV (900 mg/kg twice daily)
was given if CMVDNA was. 1000 copies/mL. The primary end-
point was a composite of CMV disease or invasive bacterial/fungal
infection or death by day 270 and the study was designed to show
superiority of VGCV prophylaxis. Follow-up was until day 640 af-
ter HCT.Neutropenia was analyzed while receiving study drug and
by day 270. All analyses were by intent-to-treat. Results: 184 pa-
tients were randomized. All patients completed follow-up through
day 270; 84% (VGCV) and 82% (Plac) completed follow-up
through day 640 (as of 9/30/2007). There was no observed differ-
ence between the groups in the primary endpoint at day 270
(VGCV: 20%, Plac: 21%, hazard ratio [HR] 1.0, 95% CI 0.5–1.9,
P 5 0.96) and 640 (39% and 40%, HR 0.9, 95% CI 0.6–1.5, P 5
0.8). Valganciclovir prophylaxis reduced CMV PCR positivity
(11% and 36%, HR 0.3, 95% 01.-0.5, P 5 0.0002). There was
a trend towards more neutropenia on double-blind study drug (ab-
solute neutrophil count [ANC]\ 1000/mm3 43% and 29%, HR
1.7, 95%CI 0.9–2.9, P5 0.08) but no significant difference was ob-
served at day 270 (HR 1.3, 95% CI 0.8–2.1, p 5 0.21 for ANC\
1000/mm3). The number and severity of adverse events AEs (in-
cluding SAEs) was similar between the groups. There was also no
significant difference in secondary endpoints, including CMV dis-
ease at day 270 (2% in both groups, HR 0.9, 95% CI 0.1–6.5) and
640 (6% and 5%, HR 1.2, 95% CI 0.3–4.5), HSV/VZV infections
by day 640, death at any time, or relapse of the underlying disease.
Conclusion: VGCV prophylaxis was not superior in reducing the
composite endpoint of CMV disease, invasive bacterial or fungal in-
fection or death. The incidence of CMV disease was low in both
groups. VGCV reduced CMV DNAemia and the need for PET.
The rate of neutropenia and other AEs was high but not signifi-
cantly different between the groups. The study was not designed
to test for equivalency.76
AN INTERNATIONAL COMPARISON OF CURRENT STRATEGIES TO PRE-
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